Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.

Park SH, Ryu MH, Ryoo BY, Im SA, Kwon HC, Lee SS, Park SR, Kang BY, Kang YK.

Invest New Drugs. 2012 Dec;30(6):2377-83. doi: 10.1007/s10637-012-9795-9. Epub 2012 Jan 25.

PMID:
22270258
2.

Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.

Montemurro M, Gelderblom H, Bitz U, Schütte J, Blay JY, Joensuu H, Trent J, Bauer S, Rutkowski P, Duffaud F, Pink D.

Eur J Cancer. 2013 Mar;49(5):1027-31. doi: 10.1016/j.ejca.2012.10.009. Epub 2012 Nov 6.

PMID:
23140824
3.

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.

Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B.

Ann Surg Oncol. 2012 May;19(5):1551-9. doi: 10.1245/s10434-011-2120-6. Epub 2011 Nov 8.

PMID:
22065192
4.

Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.

Li J, Gao J, Hong J, Shen L.

Future Oncol. 2012 May;8(5):617-24. doi: 10.2217/fon.12.29.

PMID:
22646775
5.

Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.

Yoon DH, Ryu MH, Ryoo BY, Beck M, Choi DR, Cho Y, Lee JL, Chang HM, Kim TW, Kang YK.

Invest New Drugs. 2012 Apr;30(2):819-27. doi: 10.1007/s10637-010-9593-1. Epub 2010 Nov 23.

PMID:
21104107
6.

Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours.

Pantaleo MA, Nannini M, Saponara M, Gnocchi C, Di Scioscio V, Lolli C, Catena F, Astolfi A, Di Battista M, Biasco G; GIST Study Group, University of Bologna, Bologna, Italy..

Anticancer Drugs. 2012 Jun;23(5):567-72. doi: 10.1097/CAD.0b013e328352cc50.

PMID:
22430048
7.

Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.

Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G, Boni C.

Anticancer Res. 2014 Sep;34(9):5105-10.

PMID:
25202099
8.

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, Kakeji Y, Onozawa Y, Yamasaki M, Ohtsu A.

Cancer. 2011 Oct 15;117(20):4633-41. doi: 10.1002/cncr.26120. Epub 2011 Mar 31.

9.

Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.

Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.

Acta Oncol. 2012 Apr;51(4):528-36. doi: 10.3109/0284186X.2011.636753. Epub 2011 Dec 7.

PMID:
22150077
10.

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.

Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR.

Clin Cancer Res. 2007 Aug 15;13(16):4874-81.

11.

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors.

Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L.

Cancer Chemother Pharmacol. 2011 Jul;68(1):69-77. doi: 10.1007/s00280-010-1431-9. Epub 2010 Sep 14.

12.

Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.

Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, Casali PG.

Ann Oncol. 2008 Jan;19(1):173-7. Epub 2007 Aug 14.

PMID:
17698976
13.

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.

Chen YY, Yeh CN, Cheng CT, Chen TW, Rau KM, Jan YY, Chen MF.

World J Gastroenterol. 2011 Apr 28;17(16):2113-9. doi: 10.3748/wjg.v17.i16.2113.

14.

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK.

Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23.

PMID:
19307738
15.

Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.

Roubaud G, Kind M, Coindre JM, Maki RG, Bui B, Italiano A.

Ann Oncol. 2012 Mar;23(3):804-5. doi: 10.1093/annonc/mdr631. Epub 2012 Jan 31. No abstract available.

PMID:
22294526
16.

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.

JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347.

PMID:
22453568
17.

Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients.

Li J, Gong JF, Li J, Gao J, Sun NP, Shen L.

World J Gastroenterol. 2012 Feb 21;18(7):698-703. doi: 10.3748/wjg.v18.i7.698.

18.

Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.

Lim KH, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY.

Med Oncol. 2008;25(2):207-13. doi: 10.1007/s12032-007-9014-2. Epub 2007 Oct 6.

PMID:
18488160
19.

The lack of CD34 expression in gastrointestinal stromal tumors is related to cystic degeneration following imatinib use.

Koh Y, Lee HE, Oh DY, Kim JH, Lee SH, Kim SH, Kim DW, Im SA, Kim TY, Heo DS, Kim WH, Bang YJ.

Jpn J Clin Oncol. 2012 Nov;42(11):1020-7. doi: 10.1093/jjco/hys138. Epub 2012 Sep 5.

PMID:
22952296
20.

The safety of regorafenib for the treatment of gastrointestinal stromal tumors.

Rutkowski P, Stępniak J.

Expert Opin Drug Saf. 2016 Jan;15(1):105-16. doi: 10.1517/14740338.2016.1122754. Epub 2015 Dec 11.

PMID:
26651387

Supplemental Content

Support Center